SecBot SecBot
424B5 ·Filed Apr 3, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed7mo ago SEC0001213900-26-039938
Notable filing: 424B5
Actionable Insight ▼ Bearish

This offering represents a distress capital raise from a company on the brink of delisting with no revenue stream. The dilution from raising up to $1.2 million on a $2 million market cap is extreme. Traders should anticipate continued downward pressure on the stock price, potential delisting to OTC markets, and possible bankruptcy if the company cannot secure additional funding. The offering confirms the company's survival is in serious jeopardy.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.6950
T+0 close · Apr 3, 2026 · via day close
Latest settled
+128.78%
T+60 · $1.59
Vs SPY
+115.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $0.6950entry
  2. T+1 · 7mo ago −2.16%α −2.22% · $0.6800
  3. T+5 · 7mo ago +2.59%α −1.54% · $0.7130
  4. T+20 · 7mo ago +7.63%α −1.36% · $0.7480
  5. T+60 · 5mo ago +128.78%α +115.31% · $1.59
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals is conducting an at-the-market offering of up to $1.2 million in common shares through H.C. Wainwright & Co. This offering occurs amid severe financial distress, including a Nasdaq delisting notice due to low stock price and the wind down of its only revenue-generating business segment, BayMedica, due to adverse U.S. legislation. The company faces substantial doubt about its ability to continue as a going concern.

Key Facts

  • Company is offering up to $1,213,648 in common shares through an at-the-market offering with H.C. Wainwright & Co.
  • Stock received Nasdaq delisting notice on March 27, 2026 for failing to maintain $1.00 minimum bid price for 30 consecutive days.
  • Company is winding down BayMedica, its only revenue-generating business segment, due to H.R. 5371 legislation that will prohibit aspects of its commercial business.
  • Company has incurred significant operating losses: $3.8 million for six months ended December 31, 2025 and $8.2 million for the year ended June 30, 2025.
  • Auditors have included going concern doubts in financial statements due to recurring losses and negative cash flows.
  • Market cap is only $2 million with stock trading at $0.67 per share as of April 1, 2026.

Financial Impact

Up to $1.2 million in dilutive equity issuance from a $2 million market cap company, representing up to 60% of market value. The offering comes after a $50 million shelf registration, indicating potential for significant further dilution.

dilutionmarket capliquiditygoing concern

Risk Factors

  • Substantial doubt about the company's ability to continue as a going concern
  • Imminent delisting from Nasdaq if stock price doesn't recover to $1.00
  • Complete loss of revenue stream from wind down of BayMedica operations
  • Extreme shareholder dilution from capital raise on minimal market cap
  • Potential bankruptcy if unable to secure additional financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001213900-26-039938
Document: 0001213900-26-039938-index-headers.html0001213900-26-039938
Document: 0001213900-26-039938-index.html0001213900-26-039938
Document: 0001213900-26-039938.txt0001213900-26-039938

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026